Skip to main content
Fig. 5 | BMC Medical Genomics

Fig. 5

From: SLC27A2 is a potential immune biomarker for hematological tumors and significantly regulates the cell cycle progression of diffuse large B-cell lymphoma

Fig. 5

Correlation analysis of clinical information between SLC27A2 and DLBCL and AML. SLC27A2 showed a significant upward trend in stages 1, 2, and 3 (A), with the worst prognosis in stage 3 and the highest expression of SLC27A2. In DLBCL, SLC27A2 expression levels are highest in individuals aged over 60 years (G2) (B), while in AML, SLC27A2 expression levels are lowest in individuals aged over 60 years (G2) (C)

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us